MEDI 6469

Drug Profile

MEDI 6469

Alternative Names: Anti-OX40 monoclonal antibody; MEDI-6469

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AgonOx; Providence Cancer Center
  • Developer MedImmune; Providence Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Diffuse large B cell lymphoma; Prostate cancer; Solid tumours
  • Phase I Colorectal cancer; Head and neck cancer

Most Recent Events

  • 01 Jun 2018 Efficacy and adverse events data from a phase I trial in Head and neck cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 27 Mar 2017 MedImmune terminates early a phase I/II trial in Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Second-line therapy or greater) and Diffuse large B cell lymphoma (Combination therapy, Monotehrapy, Late-stage disease) in USA at the sponsor's discretion (IV) (NCT02205333)
  • 16 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top